Edoxaban 60 MG
Sponsors
University of Florida, Portola Pharmaceuticals, University of Alberta, Turku University Hospital, Cardioangiologisches Centrum Bethanien
Conditions
Atrial FibrillationBleedingBlood Coagulation DisorderCoronary Artery DiseaseHeavy Menstrual BleedingHemorrhagic Transformation StrokeHypoalbuminemiaIschemic Stroke
Phase 1
Phase 4
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
CompletedNCT02567461
Start: 2016-03-31End: 2018-03-15Updated: 2018-04-06
Lixiana Acute Stroke Evaluation Registry
CompletedNCT03494530
Start: 2018-06-01End: 2021-12-01Updated: 2024-04-05
NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers
CompletedNCT03666650
Start: 2018-11-26End: 2019-01-08Updated: 2019-09-17
Unknown Phase
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
CompletedNCT04477837
Start: 2020-10-15End: 2024-06-15Updated: 2024-08-21
Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome
Not yet recruitingNCT07116239
Start: 2025-09-30End: 2026-02-28Target: 60Updated: 2025-08-11